Egypt Celebrates Scientist Behind 12 Drugs for Cancer, Depression and Other Diseases

Egyptian scientist Dr. Magid Abou-Gharbia (Temple University)
Egyptian scientist Dr. Magid Abou-Gharbia (Temple University)
TT

Egypt Celebrates Scientist Behind 12 Drugs for Cancer, Depression and Other Diseases

Egyptian scientist Dr. Magid Abou-Gharbia (Temple University)
Egyptian scientist Dr. Magid Abou-Gharbia (Temple University)

The Egyptian Cabinet has celebrated Egyptian scientist Dr. Magid Abou-Gharbia for winning the 2026 John Scott Award in the United States, recognizing his significant contributions to drug discovery and development, particularly treatments for cancer, depression and chronic pain.

In a statement posted on its Facebook page, the Cabinet said Abou-Gharbia holds more than 145 US patents and has helped develop nearly a dozen new drugs marketed to treat various conditions, including cancer, infectious diseases, neurological disorders, women's health conditions, bone diseases and chronic pain. He has also led multidisciplinary research teams at international scientific and pharmaceutical institutions.

The Cabinet said the John Scott Award is one of the oldest scientific honors in the United States, recognizing discoveries and innovations that benefit humanity. Abou-Gharbia was among three scientists selected for the 2026 award and received the honor at a ceremony on October 27, along with a $10,000 cash prize, in recognition of his decades of pharmaceutical research.

In a statement published on November 3, 2026, Temple University said Abou-Gharbia, Laura H. Carnell Professor and founding director of the Moulder Center for Drug Discovery Research at its School of Pharmacy, received the award for his pioneering innovations in drug discovery and development.

The university said his research has contributed to the development of nearly a dozen new medicines for a range of conditions, including cancer, infectious diseases, neurological disorders, women's health conditions, bone diseases and chronic pain.

According to the university, Abou-Gharbia was preparing to travel to Egypt to deliver a lecture when he received an unexpected email from the chair of the award's selection committee informing him that he had won. He expressed surprise, happiness and pride at the recognition.

Abou-Gharbia said he had been passionate about chemistry since childhood and viewed the award as recognition not only of his own achievements but also of the talented research teams and collaborators he had worked with over the years.

The university said Abou-Gharbia is the fifth Temple faculty member to receive the award, following Michael Klein in 2020, Masatoshi Nei in 2017, John Perdew in 2015 and Franklin Davis in 2006.

Abou-Gharbia began his career as a research scientist at Wyeth Pharmaceuticals, which was later acquired by Pfizer. He rose through the ranks to become senior vice president of drug discovery, leading research teams comprising more than 500 scientists.

Among the notable drugs he helped develop are Effexor and Pristiq, both used to treat depression; Dezocine, a painkiller; and Torisel, a treatment for kidney cancer.

Research teams under his leadership also helped develop Mylotarg, a drug introduced in 2000 that targets cancer cells while limiting the exposure of other cells to toxic substances. The treatment remains in use in chemotherapy.

The university said Abou-Gharbia returned to academia in 2008 and played a leading role in establishing the Moulder Center for Drug Discovery Research, serving as its founding director until 2020. The center was established to bring together education, scientific research and the pharmaceutical industry, helping translate laboratory discoveries into treatments for patients.

During his tenure, the center secured more than $30 million in research grants and external funding. Its research resulted in 15 US patents and the establishment of four spin-off companies.

Abou-Gharbia also served as associate dean for research at Temple University's School of Pharmacy from 2008 to 2019. He received the university's Outstanding Service Award in 2022 and was inducted into the American Chemical Society Medicinal Chemistry Hall of Fame and the New Jersey Inventors Hall of Fame.

After more than 55 years in medicinal chemistry, Abou-Gharbia continues to research and design drugs targeting alcohol and opioid addiction. He has also expressed enthusiasm for working with younger generations of researchers and students, whom he regards as the future leaders of the field.

In a report published on November 5, 2026, the American Chemical Society's Chemical & Engineering News magazine said the Board of Directors of City Trusts of Philadelphia honored the three award recipients for their contributions to the comfort, welfare and happiness of humanity.

The other recipients were Nina Jablonski of Pennsylvania State University, recognized for research that transformed the understanding of race, and Daniel Skovronsky of Eli Lilly and Company, who pioneered a first-of-its-kind diagnostic tool for Alzheimer's disease.

The magazine said the three scientists join a distinguished list of previous recipients, including Marie Curie, Thomas Edison, Irving Langmuir, who served as president of the American Chemical Society in 1929, and Glenn T. Seaborg, who led the society in 1976.



Egypt Celebrates Scientist Behind 12 Drugs for Cancer, Depression and Other Diseases

Egyptian scientist Dr. Magid Abou-Gharbia (Temple University)
Egyptian scientist Dr. Magid Abou-Gharbia (Temple University)
TT

Egypt Celebrates Scientist Behind 12 Drugs for Cancer, Depression and Other Diseases

Egyptian scientist Dr. Magid Abou-Gharbia (Temple University)
Egyptian scientist Dr. Magid Abou-Gharbia (Temple University)

The Egyptian Cabinet has celebrated Egyptian scientist Dr. Magid Abou-Gharbia for winning the 2026 John Scott Award in the United States, recognizing his significant contributions to drug discovery and development, particularly treatments for cancer, depression and chronic pain.

In a statement posted on its Facebook page, the Cabinet said Abou-Gharbia holds more than 145 US patents and has helped develop nearly a dozen new drugs marketed to treat various conditions, including cancer, infectious diseases, neurological disorders, women's health conditions, bone diseases and chronic pain. He has also led multidisciplinary research teams at international scientific and pharmaceutical institutions.

The Cabinet said the John Scott Award is one of the oldest scientific honors in the United States, recognizing discoveries and innovations that benefit humanity. Abou-Gharbia was among three scientists selected for the 2026 award and received the honor at a ceremony on October 27, along with a $10,000 cash prize, in recognition of his decades of pharmaceutical research.

In a statement published on November 3, 2026, Temple University said Abou-Gharbia, Laura H. Carnell Professor and founding director of the Moulder Center for Drug Discovery Research at its School of Pharmacy, received the award for his pioneering innovations in drug discovery and development.

The university said his research has contributed to the development of nearly a dozen new medicines for a range of conditions, including cancer, infectious diseases, neurological disorders, women's health conditions, bone diseases and chronic pain.

According to the university, Abou-Gharbia was preparing to travel to Egypt to deliver a lecture when he received an unexpected email from the chair of the award's selection committee informing him that he had won. He expressed surprise, happiness and pride at the recognition.

Abou-Gharbia said he had been passionate about chemistry since childhood and viewed the award as recognition not only of his own achievements but also of the talented research teams and collaborators he had worked with over the years.

The university said Abou-Gharbia is the fifth Temple faculty member to receive the award, following Michael Klein in 2020, Masatoshi Nei in 2017, John Perdew in 2015 and Franklin Davis in 2006.

Abou-Gharbia began his career as a research scientist at Wyeth Pharmaceuticals, which was later acquired by Pfizer. He rose through the ranks to become senior vice president of drug discovery, leading research teams comprising more than 500 scientists.

Among the notable drugs he helped develop are Effexor and Pristiq, both used to treat depression; Dezocine, a painkiller; and Torisel, a treatment for kidney cancer.

Research teams under his leadership also helped develop Mylotarg, a drug introduced in 2000 that targets cancer cells while limiting the exposure of other cells to toxic substances. The treatment remains in use in chemotherapy.

The university said Abou-Gharbia returned to academia in 2008 and played a leading role in establishing the Moulder Center for Drug Discovery Research, serving as its founding director until 2020. The center was established to bring together education, scientific research and the pharmaceutical industry, helping translate laboratory discoveries into treatments for patients.

During his tenure, the center secured more than $30 million in research grants and external funding. Its research resulted in 15 US patents and the establishment of four spin-off companies.

Abou-Gharbia also served as associate dean for research at Temple University's School of Pharmacy from 2008 to 2019. He received the university's Outstanding Service Award in 2022 and was inducted into the American Chemical Society Medicinal Chemistry Hall of Fame and the New Jersey Inventors Hall of Fame.

After more than 55 years in medicinal chemistry, Abou-Gharbia continues to research and design drugs targeting alcohol and opioid addiction. He has also expressed enthusiasm for working with younger generations of researchers and students, whom he regards as the future leaders of the field.

In a report published on November 5, 2026, the American Chemical Society's Chemical & Engineering News magazine said the Board of Directors of City Trusts of Philadelphia honored the three award recipients for their contributions to the comfort, welfare and happiness of humanity.

The other recipients were Nina Jablonski of Pennsylvania State University, recognized for research that transformed the understanding of race, and Daniel Skovronsky of Eli Lilly and Company, who pioneered a first-of-its-kind diagnostic tool for Alzheimer's disease.

The magazine said the three scientists join a distinguished list of previous recipients, including Marie Curie, Thomas Edison, Irving Langmuir, who served as president of the American Chemical Society in 1929, and Glenn T. Seaborg, who led the society in 1976.


Handwritten Draft of MLK’s ‘I Have a Dream’ Speech to Go on Display Before It’s Sold at Auction

The Rev. Dr. Martin Luther King Jr., head of the Southern Christian Leadership Conference, speaks to thousands during his "I Have a Dream" speech in front of the Lincoln Memorial for the March on Washington for Jobs and Freedom, Aug. 28, 1963, in Washington. (AP)
The Rev. Dr. Martin Luther King Jr., head of the Southern Christian Leadership Conference, speaks to thousands during his "I Have a Dream" speech in front of the Lincoln Memorial for the March on Washington for Jobs and Freedom, Aug. 28, 1963, in Washington. (AP)
TT

Handwritten Draft of MLK’s ‘I Have a Dream’ Speech to Go on Display Before It’s Sold at Auction

The Rev. Dr. Martin Luther King Jr., head of the Southern Christian Leadership Conference, speaks to thousands during his "I Have a Dream" speech in front of the Lincoln Memorial for the March on Washington for Jobs and Freedom, Aug. 28, 1963, in Washington. (AP)
The Rev. Dr. Martin Luther King Jr., head of the Southern Christian Leadership Conference, speaks to thousands during his "I Have a Dream" speech in front of the Lincoln Memorial for the March on Washington for Jobs and Freedom, Aug. 28, 1963, in Washington. (AP)

Words scrawled in blue pen — and others scratched out — give an intimate peek into the writing of what would become the Rev. Martin Luther King Jr.'s most famous speech.

Delivered Aug. 28, 1963, from the steps of the Lincoln Memorial, the “I Have a Dream” speech reflects on the shameful legacy of slavery, segregation and discrimination and looks forward with hope to future equality for the country's Black citizens. A handwritten draft of that speech goes on display in King's hometown Monday before it is sold to the highest bidder at auction in January.

The words that became most famous do not appear in the seven pages from a pad of yellow, lined paper. The “I have a dream” refrain was added by King on the spot as he stood before a crowd of tens of thousands of people gathered on the National Mall for the March on Washington.

But other key parts of the speech are there in the civil rights icon's own handwriting, including the opening lines and the powerful finish invoking an African American spiritual.

King completed the handwritten draft in his hotel room in the wee hours of the morning, less than 12 hours before it was delivered, according to Christie's, which will handle the sale of the manuscript. It was then given to assistants to be typed and sent to the media, the auction house said in a news release.

Speechwriter Edward Clayton was among the multiple advisers who helped King hash out the content of the speech. His wife, Xernona Clayton, who worked alongside him in the civil rights movement, discovered the draft in the late 1990s, three decades after her husband's death. It was in a drawer of his desk, tucked inside an envelope labeled “speech.”

“The two of them gelled with writing and words,” Xernona Clayton said in the Christie's news release. “They would go back and forth and there was such respect. Dr. King, who was a great thinker, said Ed was so good at getting his words on paper and putting them in the right place at the right time.”

Clayton knew the document was important but didn't realize it was the only remaining handwritten draft and stuck it back in the drawer, finding it there again just two years ago.

Clayton, who established the Still Marching Irrevocable Charitable Unitrust to advance causes important to her, decided after consultation with trusted advisers to sell the draft to support charities that advance her own legacy and that of King. Christie's expects the draft to fetch more than $10 million. The organizations that will benefit include the Xernona Clayton Foundation and the King Center in Atlanta.

“I am so grateful for the opportunity to give this amazing speech new life, and to give new life to people who are in need,” Clayton said. “And we cannot wait to give that first gift.”

King's two remaining living children, the Rev. Bernice King and Martin Luther King III, said in the Christie's release that they are grateful the sale will support the legacy of the movement their father helped build.

“It is poetic that the past will protect the future,” Martin Luther King III said. “We are grateful that this treasure was preserved over decades by the Clayton family. It is a remarkable piece of history that shines a light on our father’s process as he prepared to make a speech that so profoundly affected the course of the Civil Rights movement and our nation. Now, for the first time, the public will have the opportunity to be inspired by this document.”

The draft will be publicly displayed for the first time at the National Center for Civil and Human Rights in Atlanta from Monday through Sunday. It will be on view in Chicago at a date to be determined and will be shown at Christie's in New York from Jan. 15, King's birthday, through Jan. 21 before being offered for auction on Jan. 22.


Isaac, a Cat Missing Since the Brooklyn Building Collapse, Has Been Reunited with His Young Owner

In this photo provided by Flatbush Cats, Zariah Coleman and her mother Sheena Coleman pose for a photo in New York on Sunday, Nov. 15, 2026, after being reunited with their cat, Issac, who had been missing since the family evacuated from an apartment building near the Brooklyn building that partially collapsed. (Flatbush Cats via AP)
In this photo provided by Flatbush Cats, Zariah Coleman and her mother Sheena Coleman pose for a photo in New York on Sunday, Nov. 15, 2026, after being reunited with their cat, Issac, who had been missing since the family evacuated from an apartment building near the Brooklyn building that partially collapsed. (Flatbush Cats via AP)
TT

Isaac, a Cat Missing Since the Brooklyn Building Collapse, Has Been Reunited with His Young Owner

In this photo provided by Flatbush Cats, Zariah Coleman and her mother Sheena Coleman pose for a photo in New York on Sunday, Nov. 15, 2026, after being reunited with their cat, Issac, who had been missing since the family evacuated from an apartment building near the Brooklyn building that partially collapsed. (Flatbush Cats via AP)
In this photo provided by Flatbush Cats, Zariah Coleman and her mother Sheena Coleman pose for a photo in New York on Sunday, Nov. 15, 2026, after being reunited with their cat, Issac, who had been missing since the family evacuated from an apartment building near the Brooklyn building that partially collapsed. (Flatbush Cats via AP)

A cat missing since last week’s deadly Brooklyn building collapse has been found alive and reunited with his young owner, New York City officials said Sunday.

Allie Taylor, director of the Mayor’s Office of Animal Welfare, said her office worked with the veterinary nonprofit Flatbush Cats to locate Isaac and reunite him with 13-year-old Zariah Coleman.

It was a bit of good news amid the tragedy of Wednesday’s collapse, which killed eight people, injured 18 others and forced the evacuation of several nearby buildings, including one next door where Zariah lives.

Zariah and her mother told The New York Times on Sunday that workers found Isaac on Sunday in a cabinet under the kitchen sink of Zariah’s apartment after hearing a soft meow.

Zariah and her family hadn't been allowed in since the collapse, which tore off the side of her building and left a hole where her bedroom wall had been.

Waiting outside, Zariah hugged the cat’s cage as workers brought him out of her apartment building. Isaac had gone four days without food or water. After his rescue, he was taken to Flatbush Cats’ veterinary clinic for a checkup.

“I had it in my heart they would find Issac,” Zariah told the Times. “I knew they would.”

Zariah tearfully spoke about her missing cat at a news conference on Friday, telling reporters: “I just really hope they come and get our cat. He’s hiding from them, and I think he’s scared.”

Mayor Zohran Mamdani heralded Isaac and Zariah’s reunion in a social media post. He thanked Taylor’s office, the city’s Buildings Department and the nonprofit for the happy outcome.

“Isaac is now receiving the veterinary care he needs,” Mamdani said. “We’re grateful to everyone who helped bring them back together.”